08 Feb 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Dainippon Sumitomo Pharma (DSP), a pharmaceutical company headquartered in Osaka, Japan, has established a wholly owned subsidiary in Singapore as a base of operations in Southeast Asia. The subsidiary is called Sunovion Pharmaceuticals Asia Pacific.
DSP is expanding globally with its global strategic product, antipsychotic lurasidone hydrochloride (generic name) at the core. As a part of this effort, DSP has considered extending commercial operations for lurasidone hydrochloride to countries in Southeast Asia where growth is expected in the mid-to long term.
DSP will first promote business operations such as obtaining approval for and marketing lurasidone hydrochloride in Southeast Asia through partnerships with local companies. In future, using Singapore as a base of operations, DSP will consider successive expansion of its product line-ups in Southeast Asia and additionally business expansion into neighboring countries such as Australia.